{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-085347","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.544206+00:00","generated_at":"2026-06-12T23:16:24.730123+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TransCode receives Nasdaq delisting notice; equity below $2.5M requirement","bullets":["Nasdaq rejected TransCode's compliance plan to regain stockholders' equity of at least $2.5M.","Company intends to appeal to Nasdaq Hearings Panel by August 2, 2023; appeal stays delisting pending hearing.","If no appeal, common stock (RNAZ) will be suspended from trading on Nasdaq at open on August 4, 2023.","Non-compliance initially disclosed on May 16, 2023; compliance plan submitted June 30 and supplemented July 24."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-085347","json":"https://secwatch.observer/filing/0001104659-23-085347.json","markdown":"https://secwatch.observer/filing/0001104659-23-085347.md","text":"https://secwatch.observer/filing/0001104659-23-085347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923085347/0001104659-23-085347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923085347/tm2322311d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:16:24.730123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fe26f48c9a9b0b0f117c852af36ca65c17e22c9","claim":"Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"July 26, 2023, the Company received a Delisting Determination Letter from the Staff advising the Company that the Staff had determined not to accept the Company’s Compliance Plan, and that the Company’s request for an extension had been denied. If, in accordance with Nasdaq Listing Rule 5815(a), the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Staff’s decision, such request will stay any delisting action by the Staff at least until the hearing process concludes and any extension granted by the Panel expires. If the Company does not request a hearing t","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923085347/0001104659-23-085347-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}